Bioengineering
Showing 121-140 of 560 Results
-
Drew Endy
Associate Professor of Bioengineering and Senior Fellow, by courtesy, at the Hoover Institution and at the Freeman Spogli Institute for International Studies
Current Research and Scholarly InterestsWe work to strengthen the foundations and expand the frontiers of synthetic biology. Our foundational work includes (i) advancing reliable reuse of bio-measurements and -materials via standards that enable coordination of labor, and (ii) developing and integrating measurement and modeling tools for representing and analyzing living matter at whole-cell scales. Our work beyond the frontiers of current practice includes (iii) bootstrapping biotechnology tools in unconventional organisms (e.g., mealworms, wood fungus, skin microbes), and (iv) exploring the limits of whole-genome recoding and building cells from scratch. We also support strategy and policy work related to bio-safety, security, economy, equity, justice, and leadership.
-
Daniel Bruce Ennis
Professor of Radiology (Veterans Affairs) and, by courtesy, of Bioengineering
Current Research and Scholarly InterestsThe Cardiac MRI Group seeks to invent and validate methods to quantify cardiac performance. We develop methods to measure cardiac structure (DWI/DTI), function (tagging and DENSE), flow (PC-MRI), and remodeling (diffusion, T1-mapping, fat-water mapping) for pediatrics and adults.
Fundamental to our research is a set of tools for numerically optimizing gradient waveforms, Bloch simulations, and patient-specific 3D-printed cardiovascular structures connected to computer controlled flow pumps. -
Amir Esrafilian
Visiting Postdoctoral Scholar, Bioengineering
Affiliate, Wu Tsai Human Performance AllianceBioContact info: amires@stanford.edu
-
Jeffrey A. Feinstein, MD, MPH
Dunlevie Family Professor of Pulmonary Vascular Disease and Professor, by courtesy, of Bioengineering
Current Research and Scholarly InterestsResearch interests include (1) computer simulation and modeling of cardiovascular physiology with specific attention paid to congenital heart disease and its treatment, (2) the evaluation and treatment of pulmonary hypertension/pulmonary vascular diseases, and (3) development and testing of medical devices/therapies for the treatment of congenital heart disease and pulmonary vascular diseases.
